Galera Therapeutics
$0.04
21
-$0-4.65% Thursday 16:58
Statistics
Day High
0.04
Day Low
0.04
52W High
0.06
52W Low
0.02
Volume
35,001
Avg. Volume
54,324
Mkt Cap
3.09M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
11MayExpected
Expected EPS
N/A
Actual EPS
N/A
Financials
-Profit Margin
Unprofitable0Revenue
-37.91MNet Income
People Also Follow
This list is based on the watchlists of people on Stock Events who follow GRTX. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap160.66B
Merck
MRK
Mkt Cap214.76B
Pfizer
PFE
Mkt Cap140.15B
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Gilead Sciences
GILD
Mkt Cap148.78B
Novartis
NVS
Mkt Cap237.61B
Astrazeneca
AZN
Mkt Cap256.58B
Lilly(Eli) &
LLY
Mkt Cap772.28B
Teva- Pharmaceutical Industries
TEVA
Mkt Cap23.49B
About
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Show more...
CEO
Dr. J. Mel Sorensen M.D.
Employees
3
Country
US
ISIN
US36338D1081
Listings
0 Comments
Share your thoughts
FAQ
What is Galera Therapeutics stock price today?▼
The current price of GRTX is $0.04 USD — it has decreased by -4.65% in the past 24 hours. Watch Galera Therapeutics stock price performance more closely on the chart.
What is Galera Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Galera Therapeutics stocks are traded under the ticker GRTX.
Is Galera Therapeutics stock price growing?▼
GRTX stock has fallen by -6.82% compared to the previous week, the month change is a -4.65% fall, over the last year Galera Therapeutics has showed a +64% increase.
What is Galera Therapeutics market cap?▼
Today Galera Therapeutics has the market capitalization of 3.09M
When is the next Galera Therapeutics earnings date?▼
Galera Therapeutics is going to release the next earnings report on May 11, 2026.
What were Galera Therapeutics earnings last quarter?▼
GRTX earnings for the last quarter are 0.66 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Galera Therapeutics revenue for the last year?▼
Galera Therapeutics revenue for the last year amounts to 0 USD.
What is Galera Therapeutics net income for the last year?▼
GRTX net income for the last year is -37.91M USD.
How many employees does Galera Therapeutics have?▼
As of April 05, 2026, the company has 3 employees.
In which sector is Galera Therapeutics located?▼
Galera Therapeutics operates in the Health Care sector.
When did Galera Therapeutics complete a stock split?▼
Galera Therapeutics has not had any recent stock splits.
Where is Galera Therapeutics headquartered?▼
Galera Therapeutics is headquartered in Malvern, US.